CN117412753A - 布鲁顿氏酪氨酸激酶抑制剂及其使用方法 - Google Patents

布鲁顿氏酪氨酸激酶抑制剂及其使用方法 Download PDF

Info

Publication number
CN117412753A
CN117412753A CN202280039736.2A CN202280039736A CN117412753A CN 117412753 A CN117412753 A CN 117412753A CN 202280039736 A CN202280039736 A CN 202280039736A CN 117412753 A CN117412753 A CN 117412753A
Authority
CN
China
Prior art keywords
formula
compound
iii
alkyl
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280039736.2A
Other languages
English (en)
Chinese (zh)
Inventor
S·巴拉苏布拉马尼安
I·科内利森
郭玥
J·H·洛伊
K·E·帕克曼
J·A·帕尔默
U·费里帕尔
N·饶
M·S·蒂奇纳
J·D·维纳布尔
J·J·M·维纳
X·苗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN117412753A publication Critical patent/CN117412753A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN202280039736.2A 2021-06-04 2022-06-02 布鲁顿氏酪氨酸激酶抑制剂及其使用方法 Pending CN117412753A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196843P 2021-06-04 2021-06-04
US63/196,843 2021-06-04
PCT/IB2022/055154 WO2022254371A1 (en) 2021-06-04 2022-06-02 Inhibitors of bruton's tyrosine kinase and methods of their use

Publications (1)

Publication Number Publication Date
CN117412753A true CN117412753A (zh) 2024-01-16

Family

ID=82214195

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280039736.2A Pending CN117412753A (zh) 2021-06-04 2022-06-02 布鲁顿氏酪氨酸激酶抑制剂及其使用方法

Country Status (14)

Country Link
US (1) US12622910B2 (cg-RX-API-DMAC7.html)
EP (1) EP4346834A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024520630A (cg-RX-API-DMAC7.html)
KR (1) KR20240019214A (cg-RX-API-DMAC7.html)
CN (1) CN117412753A (cg-RX-API-DMAC7.html)
AU (1) AU2022284369A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023025459A2 (cg-RX-API-DMAC7.html)
CA (1) CA3220015A1 (cg-RX-API-DMAC7.html)
CL (2) CL2023003564A1 (cg-RX-API-DMAC7.html)
IL (1) IL308951A (cg-RX-API-DMAC7.html)
JO (1) JOP20230310A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023014435A (cg-RX-API-DMAC7.html)
TW (1) TW202317127A (cg-RX-API-DMAC7.html)
WO (1) WO2022254371A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11964976B1 (en) 2023-09-12 2024-04-23 King Faisal University Substituted pyrido[3′,4′:4,5]pyrrolo[3,2-c][1,6]naphthyridines as CK2 inhibitors
US20250333398A1 (en) 2024-04-30 2025-10-30 Boehringer Ingelheim International Gmbh Monoaryl and hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228889A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Monoarylic heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228895A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Hetaryl substituted indazoles and benzimidazoles as sting antagonists and the use thereof as medicament
WO2025228900A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Arylamide substituted indazoles and the use thereof as medicament
WO2025228899A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Further heterocyclic compounds as sting antagonists and the use thereof as medicament
WO2025228902A1 (en) 2024-04-30 2025-11-06 Boehringer Ingelheim International Gmbh Heterocyclic acids as sting antagonists and the use thereof as medicament

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3112415A1 (de) 1981-03-28 1982-10-07 Dynamit Nobel Ag, 5210 Troisdorf Verfahren zur chlorierung von cyclischen amiden und cyclischen vinylogen amiden
US4886646A (en) 1988-03-23 1989-12-12 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Hanging drop crystal growth apparatus and method
US5096676A (en) 1989-01-27 1992-03-17 Mcpherson Alexander Crystal growing apparatus
US5130105A (en) 1990-10-23 1992-07-14 The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration Protein crystal growth tray assembly
US5221410A (en) 1991-10-09 1993-06-22 Schering Corporation Crystal forming device
US5430150A (en) 1992-12-16 1995-07-04 American Cyanamid Company Retroviral protease inhibitors
US5300478A (en) 1993-01-28 1994-04-05 Zeneca Limited Substituted fused pyrazolo compounds
US5400741A (en) 1993-05-21 1995-03-28 Medical Foundation Of Buffalo, Inc. Device for growing crystals
WO2003016338A1 (en) 2001-08-15 2003-02-27 Parker Hughes Institute Crystal structure of the btk kinase domain
AU2005284796A1 (en) 2004-09-15 2006-03-23 Janssen Pharmaceutica, N.V. Thiazolopyridine kinase inhibitors
US7579356B2 (en) 2005-05-04 2009-08-25 Janssen Pharmaceutica Nv Thia-tetraazaacenaphthylene kinase inhibitors
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
US7605154B2 (en) 2005-08-08 2009-10-20 Janssen Pharmaceutica N.V. Substituted Thiazolo [4,5-d]pyrimidines as protein kinase inhibitors
US7427625B2 (en) 2006-02-08 2008-09-23 Janssen Pharmaceutica, N.V. Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
EP2529621B1 (en) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
WO2010056875A1 (en) 2008-11-12 2010-05-20 Cgi Pharmaceuticals, Inc. Pyridazinones and their use as btk inhibitors
EP2471789B9 (en) 2009-08-26 2015-03-25 Takeda Pharmaceutical Company Limited Fused heterocyclic ring derivative and use thereof
WO2011133609A2 (en) 2010-04-19 2011-10-27 The Translational Genomics Research Institute Methods and kits to predict therapeutic outcome of btk inhibitors
FR2978441A1 (fr) 2011-07-25 2013-02-01 Diverchim Nouveaux analogues de ceramides, leurs procedes de preparation et leurs applications dans les compositions pharmaceutiques et cosmetiques
JP2015536446A (ja) 2012-10-11 2015-12-21 ファーマサイクリックス,インク. Tecファミリーキナーゼ阻害剤療法のためのコンパニオン診断
EP2970291B1 (en) 2013-03-15 2022-05-11 Janssen Pharmaceutica, N.V. Processes and intermediates for preparing a medicament
HRP20181109T1 (hr) 2013-12-11 2018-11-02 Biogen Ma Inc. Spojevi biarila korisni za liječenje ljudskih bolesti u onkologiji, neurologiji i imunologiji
WO2015127261A1 (en) 2014-02-21 2015-08-27 Pharmacyclics, Inc. Biomarkers for predicting response of dlbcl to treatment with ibrutinib
BR112017001677A2 (pt) 2014-08-01 2018-07-17 Pharmacyclics Llc biomarcadores para predizer resposta de dlbcl ao tratamento com um inibidor de btk
SMT202100674T1 (it) * 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
JO3794B1 (ar) * 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv المركبات متعددة الحلقات كمثبطات لتيروزين كيناز بروتون
JO3793B1 (ar) 2015-12-10 2021-01-31 Janssen Pharmaceutica Nv مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
WO2018103058A1 (en) 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
WO2018103060A1 (en) * 2016-12-09 2018-06-14 Janssen Pharmaceutica Nv Inhibitors of bruton's tyrosine kinase and methods of their use
JP2023522957A (ja) 2020-04-21 2023-06-01 フラッグシップ パイオニアリング, インコーポレイテッド 二機能性分子およびその使用方法
MX2024010134A (es) 2022-02-18 2024-08-27 Janssen Pharmaceutica Nv Sintesis de inhibidores de tirosina quinasa de bruton.

Also Published As

Publication number Publication date
WO2022254371A1 (en) 2022-12-08
US12622910B2 (en) 2026-05-12
CL2023003564A1 (es) 2024-06-21
EP4346834A1 (en) 2024-04-10
TW202317127A (zh) 2023-05-01
BR112023025459A2 (pt) 2024-02-27
IL308951A (en) 2024-01-01
US20230013755A1 (en) 2023-01-19
JP2024520630A (ja) 2024-05-24
JOP20230310A1 (ar) 2023-11-29
MX2023014435A (es) 2024-03-08
AU2022284369A1 (en) 2024-01-25
CA3220015A1 (en) 2022-12-08
KR20240019214A (ko) 2024-02-14
CL2024002895A1 (es) 2025-02-14

Similar Documents

Publication Publication Date Title
US12622910B2 (en) Inhibitors of Bruton's tyrosine kinase and methods of their use
KR102203990B1 (ko) 키나제 저해제로서의 피라졸로피리미딘 화합물
US20240238291A1 (en) Combinations for treatment of cancer
US20160022683A1 (en) Combinations of bruton's tyrosine kinase inhibitors and cyp3a4 inhibitors
US20080112889A1 (en) Uses of Selective Inhibitors of HDAC8 for Treatment of T-Cell Proliferative Disorders
US10570124B2 (en) Deoxycytidine kinase binding compounds
JP2024539611A (ja) 3-フルオロ-5-(((1S,2aR)-1,3,3,4,4-ペンタフルオロ-2a-ヒドロキシ-2,2a,3,4-テトラヒドロ-1H-シクロペンタ[CD]インデン-7-イル)オキシ)-ベンゾニトリル及びそれの多形を作製するプロセス
CN108024996A (zh) 布鲁顿氏酪氨酸激酶抑制剂组合和其用途
AU2019231321B2 (en) Combination treatment of chemoresistant cancers
CA3223610A1 (en) Inhibitors of bruton's tyrosine kinase and methods of their use
JP2024538131A (ja) 膀胱癌処置のための低酸素誘導因子2(アルファ)阻害剤
HK40107411A (en) Inhibitors of bruton's tyrosine kinase and methods of their use
TW202233613A (zh) 去氧胞苷激酶抑制劑之結晶型及其用途
EA051432B1 (ru) Ингибиторы тирозинкиназы брутона и способы их применения
WO2026006739A1 (en) Bicyclic heteroaryl derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors for the treatment of certain diseases
HK40102175A (en) Inhibitors of bruton's tyrosine kinase and methods of their use
WO2022197734A1 (en) Bicyclic heteroaryl boronate derivatives as ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40107411

Country of ref document: HK